Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A pilot study to evaluate feasibility for a full-scale merit application. Specifically, for
veterans considering prolonged exposure (PE) therapy, following the model established by Foa
et al, we need to establish safety, and feasibility of quetiapine compared to treatment as
usual (TAU) which employs multiple medications commonly used for PTSD in the VA system.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio